Clinical trials: in Austria
Preterm Parturation, Preterm Premature Rupture of Membranes (PPROM)
Preterm Parturation Study
In this study (study group) non-invasively measured fetal parameters in pregnant patients with preterm premature rupture of membranes (PPROM) or preterm parturation (cervical dilation before 37+0 weeks of gestation) will be…
- Trial name
- PrePart (NCT07869160)
- Testing
- Fetal ultrasound, blood draw, vaginal swab
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Graz
Wound Healing Disorder, Post-Surgical Complication
NovoX®Cup as Primary Dressing After Breast Reduction
Breast reduction is one of the most frequently performed plastic surgeries. Studies have shown that breast reduction surgery significantly improves the patients' suffering and leads to a better health-related quality of…
- Conditions
- Wound Healing Disorder, Post-Surgical Complication, Mammaplasty
- Trial name
- NCT06420323
- Testing
- Treatment with NovoX® Cup, Treatment with Omnistrip®
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- MOSS S.p.A.
Depressive Disorder, Major
Prediction of Antidepressant Effects of Electroconvulsive Therapy
Despite its successful use for more than 80 years, the mechanisms of action of electroconvulsive therapy (ECT) are still not fully understood.
- Trial name
- NCT05630469
- Testing
- Electroconvulsive therapy
- Where
- Austria
- Volunteers
- 23 people
- Sponsor
- Medical University of Vienna
Early Breast Cancer
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal…
- Trial name
- NATALEE (NCT03701334)
- Testing
- Ribociclib, Endocrine Therapy (ET)
- Where
- 387 sites in United States, Argentina and 18 more
- Volunteers
- 5,101 people
- Sponsor
- Novartis Pharmaceuticals
Venous Leg Ulcer (VLU)
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
The main objective of this study is: To assess the efficacy and safety of EscharEx (EX-03 5% formulation) compared to placebo control,in debridement and wound bed preparation of Venous Leg Ulcers (VLU).
- Trial name
- VALUE (NCT06568627)
- Testing
- EscharEx (EX-03)
- Where
- 60 sites in United States, Austria and 7 more
- Volunteers
- 216 people
- Sponsor
- MediWound Ltd
Multiple Myeloma
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma
Multiple myeloma is the second most common haematological cancer with a cancer incidence of around 500 new cases in Austria per year .
- Trial name
- NCT04300335
- Testing
- Individual Exercise, Group Exercise
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- Medical University of Vienna
Cirrhosis
Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome
Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)
- Trial name
- LOLAbiome (NCT05737030)
- Testing
- L-ornithine L-aspartate
- Where
- Austria
- Volunteers
- 52 people
- Sponsor
- Medical University of Graz
NSCLC
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in…
- Trial name
- AVANZAR (NCT05687266)
- Testing
- Datopotamab deruxtecan, Durvalumab, Carboplatin
- Where
- 254 sites in United States, Austria and 21 more
- Volunteers
- 1,350 people
- Sponsor
- AstraZeneca
Lung Cancer, Hepatocellular Carcinoma
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of…
- Trial name
- NCT07284121
- Testing
- Atezolizumab
- Where
- 92 sites in Austria, Belgium and 6 more
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche
Non-Small-Cell Lung
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based…
- Trial name
- NCT03456063
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Nab-paclitaxel, Pemetrexed
- Where
- 117 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
- Trial name
- NCT05444257
- Testing
- VX-121/TEZ/D-IVA
- Where
- 195 sites in United States, Australia and 21 more
- Volunteers
- 822 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
ST-elevation Myocardial Infarction (STEMI), Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the…
- Trial name
- CHIP in STEMI (NCT07615023)
- Testing
- Clonal hematopoiesis assessment and cardiac magnetic resonance imaging
- Where
- Austria
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
C3 Glomerulopathy (C3G), Healthy Adult Participants
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy
This study is the first time the new medicine CPV-104 is being tested in people. CPV-104 is designed to regulate the complement system, which can be overactive in diseases such as C3 glomerulopathy (C3G), an ultra-rare kidney…
- Trial name
- Essential One (NCT07483827)
- Testing
- CPV-104
- Where
- 17 sites in Austria, Belgium and 10 more
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- eleva GmbH
Prehabilitation
High Intensity PreHab Before Major Abdominal Surgery
The risk for major cardiac cardiovascular events (MACE) within the first 30 day after surgery is nit only associated to the patient relate risk factors but also to the kind of surgery.
- Trial name
- NCT05355909
- Testing
- Individualized high intensity preoperative fitness training
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University Innsbruck
Atrial Fibrillation
Affera Global Registry
The Affera Global Registry is a prospective, global, multi-center, observational post-market registry (PMR). The purpose of this study is to describe clinical performance and safety data in a broad patient population treated with…
- Trial name
- NCT06026345
- Testing
- Affera Platform
- Where
- 20 sites in Austria, Belgium and 11 more
- Volunteers
- 540 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Metastatic Non-small Cell Lung Cancer
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in…
- Trial name
- eVOLVE-Lung02 (NCT05984277)
- Testing
- Volrustomig, Pembrolizumab, Carboplatin
- Where
- 231 sites in United States, Argentina and 23 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Prostatic Cancer, Castration-Resistant
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617)…
- Trial name
- NCT07047118
- Testing
- JSB462, AAA617
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 138 people
- Sponsor
- Novartis Pharmaceuticals
Alcohol-Associated Hepatitis
Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis
The trial is designed as a prospective, single center, open label, randomized controlled pilot study evaluating the effect of A1AT (Alpha 1 Antitrypsin) on inflammation in patients with severe AAH (alcohol-associated hepatitis).
- Trial name
- EARTH (NCT06582329)
- Testing
- Alfa1 Antitrypsin
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Medical University Innsbruck
Physical Activity, Cardiometabolic Health
Optimizing Cardiometabolic Health, Cognition and Academic Performance in Children (HAPHC)
Children and young people are moving less and less. In combination with an unhealthy diet, this has led to a sharp increase in overweight and obesity among children worldwide.
- Trial name
- NCT04956003
- Testing
- 45-minute daily physical activity
- Where
- Austria
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.
- Trial name
- NCT06804811
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 78 sites in Argentina, Austria and 12 more
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.